Miragen Therapeutics is a biotechnology company advancing new treatment for patients with diseases that are underserved by today's therapies. miRagen's most advanced program, VRDN-001, is a clinical-stage anti-IGF-1R monoclonal antibody intended for the treatment of thyroid eye disease (TED). miRagen is headquartered in Boulder, Colo., with research and development operations in Waltham, Mass.